A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs IONIS AGT LRx (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 05 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Mar 2019 Status changed from active, no longer recruiting to recruiting.
- 26 Feb 2019 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020.